Abstract:Erythropoietin (EPO) is one of the most successful biopharmaceuticals in history and is used for treating anemia of different origins. However, it became clear that EPO could also work in a neuroprotective, antiapoptotic, antioxidative, angiogenetic and neurotropic way. It causes stimulation of cells to delay cell apoptosis, especially in the central nervous system. In rodent models of focal cerebral ischemia, EPO showed an impressive reduction of infarct size by 30% and improvement of neurobehavioral outcome by nearly 40%. A large animal model dealing with ischemia and reperfusion of the spinal cord showed that EPO could reduce the risk of spinal cord injury significantly. In addition, some clinical studies tested whether EPO works in real live clinical settings. One of the most promising studies showed the innocuousness and improvements in follow-up, outcome scales and in infarct size, of EPO-use in humans suffering from ischemic stroke. Another study ended unfortunately in a negative outcome and an increased overall death rate in the EPO group. The most possible reason was the involvement of patients undergoing simultaneously systemic thrombolysis with recombinant tissue plasminogen activator. An experimental study on rats demonstrated that administration of EPO might exacerbate tissue plasminogen activator-induced brain hemorrhage without reducing the ischemic brain damage. This case shows clearly how useful animal models can be to check negative side effects of a treatment before going into clinical trials. Other groups looked in human trials at the effects of EPO on the outcome after ischemic stroke, relation to circulating endothelial progenitor cells, aneurysmal subarachnoid hemorrhage, traumatic brain injury, hemoglobin transfusion thresholds and elective first-time coronary artery bypass surgery. Most of the results were positive, but are based mostly on small group sizes. However, some of the most neglected facts when focusing on experimental setups of ischemia of the central nervous system are issues like age and comorbidities. It might be extremely worthy to consider these points for future projects, because EPO might influence all these factors.

Erythropoietin and Nonhematopoietic Effects

Erythropoietin Protects Primary Cultures of Rat Cortical Neurons from Hypoxia-Induced Toxicity Through Attenuating Both Glutamate Release and NMDA Receptor Evoked Neurotoxicity Pathway.

Physiology and pharmacology of erythropoietin

New avenues of exploration for erythropoietin

[Possible new indications for erythropoietin therapy]

Clinical Application of Erythropoietin

Erythropoietin and glial cells in central and peripheral nervous systems

The Protective Effect Of Erythropoietin On The Retina

Erythropoietin in bone homeostasis—Implications for efficacious anemia therapy

Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research

A Review of Effects of Erythropoietin in Cardiovascular Diseases

Erythropoietin and the vascular wall: the controversy continues

Neurotherapeutic potential of erythropoietin after ischemic injury of the central nervous system

Erythropoietin and its derivatives: from tissue protection to immune regulation

[Erythropoietin: indications and measurement]

Progress on Neuroprotective Effects of Erythropoietin

Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach

Erythropoietin regulates signaling pathways associated with neuroprotective events

Progress of Erythropoietin for Patients with Renal Anemia

Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion

A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia